Experience of once daily nevirapine in 93 HIV-infected patients.

Due to its long half-life (25-30 hours) the once daily administration of ne virapine would appear logical but we do not have data regarding the tolerab ility and efficacy of this schedule. We have therefore tried to evaluate th is schedule in 93 HIV-infected patients beginning a treatment containing ne virapine. The tolerability of once daily nevirapine was similar to the usua l schedule with 15% of mucocutaneous allergy. The immunologic and virologic efficacy of once daily nevirapine was confirmed with a mean RNA HIV decrea se of 1.4 log, 1.3 log, 1.1 log and 1.3 log at M1, M3, M6 and M9 respective ly. The best results were observed in naive patients. Residual plasma conce ntration of nevirapine was performed in 35 patients with a mean value of 3, 8 mg/l.